The future of high-grade glioma: Where we are and where are we going. - Wikidata - wikimedia - TriplyDB

The future of high-grade glioma: Where we are and where are we going.

The future of high-grade glioma: Where we are and where are we going.

http://www.wikidata.org/entity/Q35114090

about

Advances in the treatment of newly diagnosed glioblastoma Combination Treatment with the GSK-3 Inhibitor 9-ING-41 and CCNU Cures Orthotopic Chemoresistant Glioblastoma in Patient-Derived Xenograft Models.Golgi Phosphoprotein 3 Inhibits the Apoptosis of Human Glioma Cells in Part by Downregulating N-myc Downstream Regulated Gene 1.Toca 511 plus 5-fluorocytosine in combination with lomustine shows chemotoxic and immunotherapeutic activity with no additive toxicity in rodent glioblastoma models.In silico analysis suggests differential response to bevacizumab and radiation combination therapy in newly diagnosed glioblastoma.Re-irradiation for recurrent glioma- the NCI experience in tumor control, OAR toxicity and proposal of a novel prognostic scoring system.Patterns of response to crizotinib in recurrent glioblastoma according to ALK and MET molecular profile in two patients.Trends in Malignant Glioma Monoclonal Antibody Therapy.Drug Delivery Nanosystems for the Localized Treatment of Glioblastoma Multiforme.

P2860

Q26773514-E14B0EC3-F1B1-4750-9294-9102017A6FDA Q33869702-FE3293FE-FE8C-4891-8AB2-D3C67BDFC52C Q38742645-B5F4A022-831D-455E-848A-841DC0FCB98D Q40760304-F86CCDA8-8EB4-47B8-9173-239AF85D8BC1 Q42518693-91D4A548-0CA3-48E5-895E-C8187592FCE3 Q47169712-6298D0CA-E043-47E0-8800-F3D13FF4DB36 Q52147579-86988756-96F3-4EE3-B7BE-25D0F28C71A3 Q54942652-9FC1F05A-DE4D-4073-BD74-B5E04B215B5F Q54970083-857861EC-91FF-40BD-ABDD-BDB703D34F5B

P2860

The future of high-grade glioma: Where we are and where are we going.

http://www.wikidata.org/entity/Q35114090

description

2015 nî lūn-bûn

@nan

2015 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

The future of high-grade glioma: Where we are and where are we going.

@ast

The future of high-grade glioma: Where we are and where are we going.

@en

type

label

The future of high-grade glioma: Where we are and where are we going.

@ast

The future of high-grade glioma: Where we are and where are we going.

@en

prefLabel

The future of high-grade glioma: Where we are and where are we going.

@ast

The future of high-grade glioma: Where we are and where are we going.

@en

P1433

Q35114090-EF2C3B04-91B7-42BA-8518-0D2E488B85D8

P1476

Q35114090-D7CD054C-39AF-4BED-A610-A6D486558EC7

P2093

Q35114090-088DBA72-EBD6-41C2-8F5B-DBE8817D6E44

Q35114090-226F0E00-D4CA-4374-B885-8A1882C415CC

Q35114090-F90D7BD0-94C9-493B-99FA-313FB513BB9C

P2860

Q35114090-00A59480-4EC1-4D6A-8C7F-BC78FA05442D

Q35114090-021BB1BB-96CD-409C-80BA-9D5796917E8B

Q35114090-023EAA26-4891-4E92-843F-D4ADF1BF75B2

Q35114090-02972246-1E98-4CEE-A052-111E92830760

Q35114090-0352FE53-BC3E-499C-9569-81F8B98B1F59

Q35114090-04B1273A-85F8-472C-93BD-EC5AAF2A6C06

Q35114090-04C168E8-CD03-4A82-BD1F-50DB821F5089

Q35114090-05140159-B002-474F-847C-ED0432C39EAD

Q35114090-05A960D9-22F9-4BCE-B712-B616BA44CB29

Q35114090-05CC7EDC-9F4F-4E3B-B359-CFBCA823DCC8

P304

Q35114090-D4586C32-609C-4413-B739-F2209DFCBC66

P31

Q35114090-9E6F3E1A-B16F-44E4-9D4F-B0022006C948

P356

Q35114090-181B60D3-8AA8-49D5-89EF-338D4C407319

P407

Q35114090-3D2B0CFC-2DA6-4A86-BEA5-6C3961461FEA

P433

Q35114090-0CE71590-E0F8-4BFA-BB9F-E221960C62B3

P478

Q35114090-966BE76B-BBA3-438C-B830-9CD5233389B8

P577

Q35114090-E4367964-7D3A-41E4-AC2F-473455CCFFE9

P698

Q35114090-EAA532F2-B300-4F83-803D-9CF75ED8B9B1

P932

Q35114090-9E45419F-EE9D-4937-BAF9-2E5082F6AD67

P356

2152-7806.151331

P1433

Surgical Neurology International

P1476

The future of high-grade glioma: Where we are and where are we going.

@en

P2093

Emilie Le Rhun

http://www.w3.org/2001/XMLSchema#string

Marc C Chamberlain

http://www.w3.org/2001/XMLSchema#string

Sophie Taillibert

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

β1 integrin targeting potentiates antiangiogenic therapy and inhibits the growth of bevacizumab-resistant glioblastoma

IDH1 and IDH2 mutations in gliomas

Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors

The 2007 WHO classification of tumours of the central nervous system

The natural history of EGFR and EGFRvIII in glioblastoma patients

Molecular biology of high-grade gliomas: what should the clinician know?

Targeting oncogenic ALK and MET: a promising therapeutic strategy for glioblastoma

P304

S9-S44

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4103/2152-7806.151331

http://www.w3.org/2001/XMLSchema#string

P407

P433

Suppl 1

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P577

2015-02-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25722939

http://www.w3.org/2001/XMLSchema#string

P932

4338495

http://www.w3.org/2001/XMLSchema#string